A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants

With Moderate to Severe Hidradenitis Suppurativa

(BE HEARD II)

ID #NCT04242498

Recruitment Status: recruiting as of August 2020

 

Estimated Completion Date: May of 2023

Sponsors and Collaborators: UCB Biopharma SRL

Information provided by (Responsible Party): UCB Biopharma SRL

Brief Summary: The purpose of the study is to test the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS).

Please link for complete details https://clinicaltrials.gov/ct2/show/NCT04242498

Locations: multiple locations please refer to link above for further information.

Contact: UCB Cares 1844599 ext 2273 UCBCares@ucb.com

Get Updates

Affiliated With

  • Instagram
  • Twitter
  • Facebook Social Icon
  • Pinterest

© 2020 by HS Connect   |  HSConnect.org@gmail.com  |  Hidradenitis Suppurativa Online

PO Box 73244 Puyallup, WA 98373  |  253.256.1579